



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMADOC-1700519818-1855225

European Medicines Agency decision

EMA/PE/0000228776

of 28 January 2025

on the acceptance of a modification of an agreed paediatric investigation plan for abemaciclib (Verzenios), in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

EMA/PE/0000228776

of 28 January 2025

on the acceptance of a modification of an agreed paediatric investigation plan for abemaciclib (Verzenios), in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0021/2020 issued on 6 January 2020, the decision P/0439/2021 issued on 29 October 2021, the decision P/0313/2023 issued on 9 August 2023 and the decision P/0038/2024 issued on 7 February 2024,

Having regard to the application submitted by Eli Lilly And Company Limited on 9 September 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 December 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for abemaciclib (Verzenios), are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Eli Lilly And Company Limited, 8, Arlington Square West, Downshire Way, Bracknell, RG12 1PU, United Kingdom.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMADOC-1700519818-1684000
Amsterdam, 13 December 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA/PE/0000228776

Scope of the application

Active substance(s):

Abemaciclib

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of glioma

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral solid dosage form

Route(s) of administration:

Oral use

Gastric use

Name/corporate name of the PIP applicant:

Eli Lilly And Company Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Eli Lilly And Company Limited submitted to the European Medicines Agency on 9 September 2024 an application for modification of the agreed paediatric investigation plan as set out in the European Medicines Agency's decision P/0021/2020 issued on 6 January 2020, the decision P/0439/2021 issued on 29 October 2021, the decision P/0313/2023 issued on 9 August 2023 and the decision P/0038/2024 issued on 7 February 2024.

The application for modification proposed changes to the agreed paediatric investigation plan.



The procedure started on 14 October 2024.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Paediatric Committee members of Liechtenstein and Norway agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of glioma

2.1.1. Indication(s) targeted by the PIP

Treatment of newly diagnosed patients with high-grade glioma

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate oral solid dosage form

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Development of an age-appropriate film-coated tablet. Study 2 Development of an age-appropriate oral solid dosage form.
Non-clinical studies	Study 3 Juvenile toxicity study to assess potential brain and pancreas toxicity of abemaciclib following repeated dosing to juvenile rats. (Juvenile toxicity study).
Clinical studies	Study 4 Open label, dose escalation trial to evaluate pharmacokinetics, safety and tolerability of abemaciclib in combination with irinotecan and temozolomide (triplet combination) and abemaciclib in combination with temozolomide (doublet combination) in children less than 18 years of age and weighing at least 10 kg and with BSA at least 0.5 m ² (and adults) with relapsed or refractory solid tumours. (Dose Escalation study). Study 5 Open label, randomised, controlled study to evaluate safety and efficacy of abemaciclib in combination with temozolomide, compared to temozolomide

	monotherapy, in children from birth to less than 18 years of age (and adults) with newly diagnosed high-grade glioma (HGG). (Newly diagnosed HGG).
Extrapolation, modelling and simulation studies	Study 6 Modelling and simulation study to develop a mechanistic population PK model to define PK parameters of the product in children from birth to less than 18 years of age.
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2028
Deferral for one or more measures contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of breast cancer

Authorised indication(s):

- Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence. In pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.
 - Invented name(s): Verzenios
 - Authorised pharmaceutical form(s): Film-coated tablet
 - Authorised route(s) of administration: Oral use
 - Authorised via centralised procedure

- Verzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.
 - Invented name(s): Verzenios
 - Authorised pharmaceutical form(s): Film-coated tablet
 - Authorised route(s) of administration: Oral use
 - Authorised via centralised procedure